Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals is holding its 2026 annual shareholder meeting on July 30, 2026 in Kennesaw, Georgia. Shareholders will vote on electing six directors, increasing the 2019 Omnibus Incentive Plan share reserve by 200,000 shares, ratifying Cherry Bekaert as auditor for 2026, and approving 2025 executive pay on an advisory basis.
Shareholders of record as of June 1, 2026, when 2,768,032 common shares were outstanding, are entitled to vote in person or by proxy, including online and telephone options.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of common stock. He bought 2,067 shares on June 15, 2026 at $2.22 per share, bringing his directly held position to 19,198 shares of Processa Pharmaceuticals common stock.
In addition to these directly owned shares, he is also reported as having indirect ownership of 1,009 shares through CorLyst, LLC, 432 shares through Family Entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. On this transaction date, he bought 2,654 shares of common stock at a price of $2.22 per share. Following the purchase, his direct holdings increased to 13,412 shares of common stock.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,465 shares of Common Stock at $2.22 per share. Following this trade, his directly held Common Stock position increased to 12,435 shares.
Ng also reports indirect ownership of Common Stock, including 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account labeled George Ng IRRA FOB George Ng.
Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin bought 1,831 shares of Common Stock in an open-market transaction at $2.22 per share. Following this purchase, he directly owns 11,007 shares and reports 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals, Inc. Chief Administrative Officer Wendy Guy reported an open-market purchase of 2,118 shares of common stock at $2.22 per share on June 15, 2026. After this transaction, Guy directly holds 11,958 common shares and has an additional 333 shares reported as indirectly owned through CorLyst, LLC.
Processa Pharmaceuticals, Inc. director and President of Research & Development David Young reported an open-market purchase of 1,786 shares of common stock at $2.57 per share on May 29, 2026. Following this transaction, he directly holds 17,131 common shares.
The filing also lists indirect holdings of common stock, including 742 shares held through CorLyst, LLC, 432 shares held through family entities, and 1,242 shares held through the Young-Plaisance Revocable Trust as of the same date.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of Common Stock. On May 29, 2026, he bought 2,292 shares at $2.57 per share, bringing his directly held position to 10,758 shares after the transaction.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,129 shares of Common Stock at $2.57 per share on May 29, 2026. Following this transaction, his direct holdings increased to 9,970 Common Stock shares.
The filing also lists indirect ownership positions of 800 Common Stock shares held through the Ng Cha Family Trust and 3,488 Common Stock shares held through an account labeled George Ng IRRA FOB George Ng, reflecting additional indirect exposure to Processa shares.
Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought additional company stock. On an open-market purchase, he acquired 1,582 shares of common stock at $2.57 per share. After this trade, he directly owns 9,176 shares. A separate holding entry shows 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.